Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Combined endpoint may support personalised medicine in ulcerative colitis

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By
Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
Phase 3, SELECTION
A combined clinical, biological, health-related quality of life, and endoscopic endpoint displayed improvements for participants with ulcerative colitis (UC) treated with filgotinib compared with placebo. In addition, the novel endpoint was strongly associated with general quality-of-life measures. Holistic assessments of participants via a combined endpoint are useful to identify super responders and may support personalised medicine. Prof. Stefan Schreiber (Christian-Albrecht University, Germany) argued that traditional outcomes do not consider the comprehensiveness of the individual patients’ experience. Holistic assessments may help to identify patients in whom therapies demonstrate the largest effect and lead to disease control [1]. A combined endpoint was evaluated in the 200 mg filgotinib and placebo arms of the SELECTION trial (NCT02914522), a phase 2b/3 st...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on